Completed PHASE1/PHASE2 INTERVENTIONAL NCT00084214

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma

Sponsor: Synta Pharmaceuticals Corp.

Conditions Melanoma

Updated 7 times since 2017 Last updated: Mar 5, 2014 Started: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Melanoma, this trial is completed. The trial is conducted by Synta Pharmaceuticals Corp. and has accumulated 7 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Synta Pharmaceuticals Corp.

Data source: Synta Pharmaceuticals Corp.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Bismarck, United States , Bloomington, United States , Charlotte, United States , Columbia, United States , Danville, United States , Goshen, United States , Honolulu, United States , Hot Springs, United States and 18 more locations